Patritumab deruxtecan, an antibody–drug conjugate (ADC) which contains a topoisomerase I inhibitor payload, was investigated in the phase II HERTHENA-Lung01 study in patients with advanced EGFR-mutated NSCLC who had progressed following EGFR TKI and platinum-based chemotherapy [112]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.